DNMT1 and colorectal carcinoma: Furthermore, acquired resistance to 5-FU induces hypermethylation of the LY6G6D promoter in CRC cells, confirming recent observations that DNMT inhibitors given in combination with standard with 5-FU or oxaliplatin improve therapeutic responses in patients with CRC [34].